sotorasib at a glance
Medicine class
Targeted anticancer treatment and selective KRAS G12C inhibitor
Licensed role
Previously treated, locally advanced or metastatic non-small cell lung cancer with a confirmed KRAS G12C mutation
Biomarker testing
The tumour's KRAS G12C mutation must be confirmed using a validated test before treatment
Food
Tablets may be taken with or without food
What is sotorasib used for?
The selected UK product is licensed as monotherapy for:
Adults with KRAS G12C-mutated, locally advanced or metastatic non-small cell lung cancer whose disease has progressed after, or who cannot tolerate, platinum chemotherapy and/or anti-PD-1 or anti-PD-L1 immunotherapy.
How does sotorasib work?
Sotorasib binds permanently and selectively to the abnormal KRAS G12C protein, locking it in an inactive state. This interrupts signals that support the growth and survival of tumour cells carrying that mutation, while not directly inhibiting normal KRAS.
sotorasib preparations and strengths
Tablet
Route: Oral
Strengths: 240 mg
How to take sotorasib
Follow the cancer team's instructions and do not change or stop treatment without discussing it with them.
Take the tablets with or without food.
Swallow tablets whole if possible.
If swallowing is difficult, disperse the tablets without crushing in at least 120 mL of non-carbonated, room-temperature water. Stir gently, drink promptly, then rinse the container with another 120 mL of water and drink the rinse.
Discard a prepared dispersion if it has not been taken within two hours.
Administration through a suitable feeding tube may be possible under healthcare-professional guidance.
sotorasib side effects
Common or expected effects
- Diarrhoea or constipation
- Nausea, vomiting or abdominal pain
- Joint, muscle or back pain
- Tiredness
- Cough or breathlessness
- Reduced appetite
- Anaemia
- Abnormal liver blood tests
Get urgent medical advice
- New or worsening breathlessness, cough or fever, suggesting interstitial lung disease or pneumonitis
- Yellow skin or eyes, dark urine, pale stools, unusual bruising, marked weakness or right-sided abdominal pain, suggesting liver injury
- Severe or persistent diarrhoea or vomiting
sotorasib in pregnancy
There are no adequate human pregnancy data, and animal studies found reproductive toxicity. Sotorasib may pose a hazard to the fetus; pregnancy, suspected pregnancy or plans to conceive require prompt discussion with the oncology and maternity teams.
sotorasib while breastfeeding
It is unknown whether sotorasib or its metabolites enter human milk, and risk to a breastfed child cannot be excluded. A specialist should weigh the benefits of breastfeeding against the need for treatment when deciding which to stop.
sotorasib interactions
Sotorasib has clinically important interactions. Check prescription, non-prescription and herbal products before treatment and whenever medicines change.
Proton-pump inhibitors and H2-receptor antagonists
Medicines such as omeprazole or famotidine reduce sotorasib exposure and may reduce its effect; specialist administration instructions are needed if concurrent use is unavoidable.
Local antacids
Antacids containing substances such as calcium carbonate or magnesium hydroxide must be separated from sotorasib according to the product instructions.
Strong CYP3A4 inducers
Rifampicin, carbamazepine, phenytoin, phenobarbital and St John's wort may lower sotorasib exposure, so concurrent use is not recommended.
Common questions about sotorasib
Answers are fully visible for fast scanning and source review.
What type of cancer does sotorasib treat?
It is licensed for certain adults with previously treated, locally advanced or metastatic non-small cell lung cancer carrying a KRAS G12C mutation.
Why is a KRAS test needed before sotorasib?
Sotorasib specifically targets KRAS G12C. A validated tumour test must confirm this mutation because cancers without it are not covered by the licensed indication.
Is sotorasib chemotherapy?
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.